{"id":17673,"date":"2025-10-20T13:13:43","date_gmt":"2025-10-20T17:13:43","guid":{"rendered":"https:\/\/aseq-ehaq.ca\/?page_id=17673"},"modified":"2025-10-20T13:14:32","modified_gmt":"2025-10-20T17:14:32","slug":"why-international-mcs-consortium-matters","status":"publish","type":"page","link":"https:\/\/aseq-ehaq.ca\/en\/why-international-mcs-consortium-matters\/","title":{"rendered":"Why International MCS Consortium Matters"},"content":{"rendered":"\n<p>Multiple Chemical Sensitivity is not confined to a single country or population, but is a significant and growing global health concern.<\/p>\n\n\n\n<p><strong>Key statistics:<\/strong><\/p>\n\n\n\n<p>Notable Statistics<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Nearly <strong>20%<\/strong> of people across the USA, UK, Australia, and Sweden report chemical sensitivity, and <strong>7.4%<\/strong> have been diagnosed with MCS.<\/li>\n\n\n\n<li>In the USA, almost <strong>26%<\/strong> report chemical sensitivity, with <strong>13%<\/strong> diagnosed with MCS \u2014 a three-fold increase since 2003.<\/li>\n\n\n\n<li>In Australia, nearly <strong>3 million people<\/strong> are affected; over <strong>55%<\/strong> of those with MCS report disabling health effects upon chemical exposure.<\/li>\n\n\n\n<li>In the UK, <strong>5.7 million adults<\/strong> report chemical sensitivity and <strong>2.3 million<\/strong> have been diagnosed with MCS.<\/li>\n\n\n\n<li>Studies in Japan, Korea, and Denmark also confirm prevalence rates between <strong>6% and 11%<\/strong>, underlining that MCS is a global issue.<\/li>\n<\/ul>\n\n\n\n<p>These findings highlight the urgent need for <strong>coordinated international research, clinical guidance, and policy development<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Multiple Chemical Sensitivity is not confined to a single country or population, but is a significant and growing global health concern. Key statistics: Notable Statistics These findings highlight the urgent need for coordinated international research, clinical guidance, and policy development.<\/p>\n","protected":false},"author":15,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-17673","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/aseq-ehaq.ca\/en\/wp-json\/wp\/v2\/pages\/17673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aseq-ehaq.ca\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/aseq-ehaq.ca\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/aseq-ehaq.ca\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/aseq-ehaq.ca\/en\/wp-json\/wp\/v2\/comments?post=17673"}],"version-history":[{"count":0,"href":"https:\/\/aseq-ehaq.ca\/en\/wp-json\/wp\/v2\/pages\/17673\/revisions"}],"wp:attachment":[{"href":"https:\/\/aseq-ehaq.ca\/en\/wp-json\/wp\/v2\/media?parent=17673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}